Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273375 · ClinicalTrials.gov registry record · Phase 3
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Canadian Cancer Trials Group.
- Active
- Registry status
- Phase 3
- Development phase
- 1,415
- Enrollment target
- 20
- Study locations
NCT02273375 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Canadian Cancer Trials Group. The registered enrollment target is 1,415 participants, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02273375, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Canadian Cancer Trials Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,415 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MEDI4736
Study Locations (20)
New South Wales
- Campbelltown Hospital - Campbelltown
- Chris O'Brien Lifehouse - Camperdown
- Coffs Habour Health Campus - NCCI - Coffs Harbour
- Gosford Hospital - Gosford
- Nepean Hospital - Kingswood
- St. George Hospital, Cancer Care Centre - Kogarah
- Liverpool Cancer Therapy Centre, Liverpool Hospital - Liverpool
- Northern Cancer Institute St Leonards - St Leonards
- Westmead Hospital - Westmead
Pennsylvania
- Hematology and Oncology Associates of NEPA - Dunmore
- Thomas Jefferson University - Philadelphia
- The Reading Hospital Medical Center - West Reading
Florida
- University of Florida - Gainesville
- H. Lee Moffitt Cancer Center - Tampa
Queensland
- Sunshine Coast University Hospital - Birtinya
- Princess Alexandra Hospital - Brisbane
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- USC Norris/Comprehensive Cancer Centre - Los Angeles
Colorado
- National Jewish Health - Denver
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2015-02-24 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02273375
The ClinicalTrials.gov registry entry for NCT02273375 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,415 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (116% higher). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02273375 reports 20 study locations spanning 8 distinct geographic areas - top geographies include New South Wales, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT02273375 about?
NCT02273375 is a clinical study titled "Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC". The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
What is the current status of trial NCT02273375?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,415 participants. The study started on 2015-02-24. Estimated completion is 2026-01-31.
What conditions does trial NCT02273375 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02273375?
The interventions under investigation include: Placebo (DRUG), MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02273375?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02273375 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.